Citi maintained a neutral rating on Novo Nordisk following the failure of its heart drug ziltevekimab in the ZEUS trial, which showed no benefit over placebo in reducing cardiovascular events. Despite this setback, the drug's expected peak sales are modest and factored into valuations. Citi highlighted ongoing concerns about pricing and competition in the obesity drug market, particularly from rivals like Eli Lilly and new oral GLP-1 formulations. Investors are advised to await upcoming trial results in 2027 before making further decisions.
Citi maintains a neutral rating on Novo Nordisk after its anti-inflammatory drug ziltevekimab failed to meet the primary endpoint in a heart disease trial. The trial showed no significant benefit over placebo and raised safety concerns. While Citi vi...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
As employers increasingly drop insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, major retailers such as Walmart, Costco, CVS, and Amazon are expanding direct-to-consumer prescription programs to capture market share. These pro...
Novo Resources Corp is starting a 2,700-metre reverse circulation drilling program at its Tibooburra Gold Project in New South Wales. The drilling will focus on extending high-grade gold mineralisation at the Clone prospect, where previous results sh...
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...
